Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Pomalidomide
19171-19-8

Pomalidomide synthesis

5synthesis methods
Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.
Synthetic Routes
  • ROUTE 1
  • 202112070565840225.jpg

    Huang, Daowei; Shen, Chengwu; Wang, Wenya; Huang, Lei; Ni, Feng; Li, Jianqi. New synthesis route for the preparation of pomalidomide. Synthetic Communications. Volume 46. Issue 16. Pages 1343-1348. Journal; Online Computer File. (2016).

  • ROUTE 2
  • 202112078615372472.jpg

    Wu, Gang; Cen, Jun-da. Improved synthesis of antitumor agent pomalidomide. Zhongguo Yaowu Huaxue Zazhi. Volume 23. Issue 2. Pages 108-110. Journal. (2013).

  • ROUTE 3
  • 202112078446013598.jpg

    : Tang, Mei; Wu, Han; Zhang, Aiying; Liu, Zenglu; Mao, Zhenmin. Synthesis of antitumor agent pomalidomide. Zhongguo Yiyao Gongye Zazhi. Volume 40. Issue 10. Pages 721-723. Journal. (2009).

  • ROUTE 4
  • 202112075689815837.jpg

    Crews, Craig M.; Burslem, George; Cromm, Philipp M.; Jaime-Figueroa, Saul; Toure, Momar. Preparation of imide-based compounds as modulators of proteolysis and methods of use. Assignee Yale University, USA. WO 2019148055. (2019).

  • ROUTE 5
  • 202112074223166876.jpg

    Barman, Dhiren Chandra; Ram, Sita; Rajbangshi, Mantu; Nath, Asok; Prasad, Mohan. Process for the preparation of pomalidomide. Assignee Sun Pharmaceutical Industries Limited, India. WO 2018154516. (2018).

  • ROUTE 6
  • 202112073990566308.jpg

    : Li, Jianqi; Huang, Daowei; Zhou, Ainan; Liu, Yu; Zhu, Meiyu. A process for preparing pomalidomide for treatment of multiple myeloma via intramolecular cyclization. Assignee Shanghai Institute of Pharmaceutical Industry, Peop. Rep. China; China State Institute of Pharmaceutical Industry. CN 103724323. (2014).

  • ROUTE 7
  • 202112071796278882.jpg

    : Ni, Cheng; Chen, Hongxiang; Jiang, Weibin; Tang, Jiantuo. Process for preparation of Pomalidomide. Assignee Hangzhou Heze Pharmaceutical Technology Co., Ltd., Peop. Rep. China. CN 105440013. (2016).

202112070565840225.jpg

Huang, Daowei; Shen, Chengwu; Wang, Wenya; Huang, Lei; Ni, Feng; Li, Jianqi. New synthesis route for the preparation of pomalidomide. Synthetic Communications. Volume 46. Issue 16. Pages 1343-1348. Journal; Online Computer File. (2016).

-

Yield:19171-19-8 96.6%

Reaction Conditions:

with sodium acetate in acetonitrile; for 4 h;Reflux;

Steps:

2 Example 2 The production (R/S)-4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione (1)

40.0 g (170.8 mmol) of ethyl 4-amino-1,3-dioxo-1,3-dihydro-2H-isomdole-2-carboxylate, 800 cm3 of acetonitrile, 28.4 g (342.0 mmol) of anhydrous sodium acetate, 28.1 g (170.7 mmol) of 3-aminopiperidine-2,6-dione are measured into a 1000 cm3 round-bottomed flask, then the suspension obtained in this way is heated to reflux temperature. The stirring is continued at unchanged temperature for 4 hours. The reaction mixture is concentrated to about 40 cm3 at 40 °C with the help of a vacuum. 800 cm3 of distilled water is added to the concentrated residue, which is then stirred at room temperature for 30 minutes. (The water may also be added at an earlier stage.) Following this the crystalline product is filtered, washed with 2x400 cm3 of distilled water, then dried at 50 °C in a vacuum until constant weight is achieved. In this way 45.10 g (96.6%) of the product according to the title is obtained. Mp. : 314-315 °C (decomposes) IR (KBr): 3481 , 3378, 3248, 1752, 1703, 1635, 1362, 1197 cm 1. 1H NMR (DMSO-d6, 400 MHz): δ = 11.10 (b, 1H), 7.47 (m, 1H), 7.02 (m, 1H), 7.00 (m, 1H), 5.06 (m, 1H), 2.89 (m, 1H), 2.58 (m, 1H), 2.56 (m, 1H), 2.03 (m, 1H) ppm. HPLC: Waters Acquity UPLC BEH C18; 2.1 x50 mm; 1.7 μm; 0.5 mL/min; 225 nm; 10/90 CH3CN/0.1 % HClO4 (aq); 1.38 min (99.90%).

References:

WO2017/134476,2017,A1 Location in patent:Page/Page column 16

Pomalidomide Related Search: